Acquisition by Fletcher Aaron G.l. of 54009 shares of Cognition Therapeutics at 1.4 subject to Rule 16b-3
| CGTX Stock | USD 0.34 0.01 3.03% |
Slightly above 56% of all Cognition Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Cognition Therapeutics suggests that some traders are interested. Cognition Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Cognition Therapeutics' earnings reports, geopolitical events, and overall market trends.
Cognition | Build AI portfolio with Cognition Stock |
Filed transaction by Cognition Therapeutics Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cognition Therapeutics Fundamental Analysis
We analyze Cognition Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cognition Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cognition Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Cognition Therapeutics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Cognition Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cognition Therapeutics stock to make a market-neutral strategy. Peer analysis of Cognition Therapeutics could also be used in its relative valuation, which is a method of valuing Cognition Therapeutics by comparing valuation metrics with similar companies.
Peers
Cognition Therapeutics Related Equities
| BOLT | Bolt Biotherapeutics | 13.79 | ||||
| KOD | Kodiak Sciences | 9.43 | ||||
| RNAZ | Transcode Therapeutics | 4.63 | ||||
| AUTL | Autolus Therapeutics | 3.38 | ||||
| CGEM | Cullinan Oncology | 2.46 | ||||
| DAWN | Day One | 1.54 | ||||
| DRMA | Dermata Therapeutics | 2.41 | ||||
| GANX | Gain Therapeutics | 2.55 | ||||
| LTRN | Lantern Pharma | 3.06 | ||||
| EYEN | Eyenovia | 4.24 | ||||
| TCRX | Tscan Therapeutics | 5.34 | ||||
| CUE | Cue Biopharma | 5.63 | ||||
| INAB | In8bio | 13.33 |
Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.